A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant-Reference-Cited by-同舟云学术

A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant

Published:2019-12-18 Issue:2 Volume:99 Page:331-341
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Martino Massimo^ORCID,Gori Mercedes,Tripepi Giovanni,Recchia Anna Grazia,Cimminiello Michele,Provenzano Pasquale Fabio,Naso Virginia,Ferreri Anna,Moscato Tiziana,Console Giuseppe,Loteta Barbara,Gallo Giuseppe Alberto,Gentile Massimo,Innao Vanessa,Rossi Marco,Morabito Antonella,Vincelli Iolanda Donatella,Mannina Donato,Pitino Annalisa

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-019-03901-w.pdf

Reference50 articles.

1. Goldschmidt H, Ashcroft J, Szabo Z, Garderet L (2019) Navigating the treatment landscape in multiple myeloma: which combinations to use and when? Ann Hematol 98:1–18. https://doi.org/10.1007/s00277-018-3546-8

2. Martin T, Huff CA (2019) Multiple myeloma: current advances and future directions. Clin Lymphoma Myeloma Leuk 19:255–263

3. Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT et al (2014) Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 371:895–905

4. Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, Siniscalchi A, Magarotto V, Pour L, Carella A, Malfitano A, Petrò D, Evangelista A, Spada S, Pescosta N, Omedè P, Campbell P, Liberati AM, Offidani M, Ria R, Pulini S, Patriarca F, Hajek R, Spencer A, Boccadoro M, Palumbo A (2015) Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol 16:1617–1629

5. Cavo M, Palumbo A, Zweegmanet S, Dimopoulos MA, Hajek R, Pantani L et al (2016) Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): a randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial). J Clin Oncol 34(15_suppl):8000–8000. https://doi.org/10.1200/JCO.2016.34.15_suppl.8000

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of biosimilar pegfilgrastim in patients with lymphoma after high-dose chemotherapy and autologous stem cell transplantation: a real-life study;Frontiers in Hematology;2024-07-25

2. Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022;International Journal of Clinical Oncology;2024-04-23

3. Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: A systematic review and meta-analysis from Clinical Practice Guidelines for the Use of G-CSF 2022;2024-01-12

4. Long-acting granulocyte colony-stimulating factor pegfilgrastim (lipegfilgrastim) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation;International Journal of Hematology;2021-07-02

5. Treatment of Multiple Myeloma and the Role of Melphalan in the Era of Modern Therapies—Current Research and Clinical Approaches;Journal of Clinical Medicine;2021-04-23